– IRELAND, Dublin – Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the appointment of Sanjiv Patel to its Board of Directors.
“Sanjiv is an experienced leader with significant industry experience that uniquely positions him to guide us as we look towards transitioning to a fully integrated research, development and commercial biotechnology company,” said Board Chairman, Dr. Lars Ekman. “We welcome Sanjiv to our Board and look forward to his contributions in advising Prothena during this transformational period.”
About Sanjiv Patel
Sanjiv K. Patel, MBBS is President, CEO, and a member of the board of Relay Therapeutics, a clinical-stage precision medicine company. Before joining Relay Therapeutics, Dr. Patel served in various roles at Allergan, Inc. for over a decade. He most recently served as Allergan’s EVP, Chief Strategy Officer, and previously as Corporate VP, Global Strategic Marketing and Global Health Outcomes. Before this, he was a management consultant at The Boston Consulting Group and practiced as a surgeon within the UK’s National Health Service.
“I’m excited to join the Board at this pivotal stage for Prothena. The Company’s leading protein dysregulation expertise is clearly reflected in its robust and promising pipeline of novel programs in areas of high unmet need,” said Dr. Patel. “I look forward to working with the Prothena team to contribute strategically to the Company’s continued growth.”
Dr. Patel earned his MBBS from the University of London, his MA in Medical Sciences from the University of Cambridge, his MRCS from the Royal College of Surgeons of England, and his MBA from INSEAD.
About Prothena
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics, built on protein dysregulation expertise, with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for several indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease, and several other neurodegenerative diseases.
For more information: https://www.prothena.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.